Signatope develops a biomarker assay system capable of detecting and quantifying biomarkers for organ damage and drug interactions in blood, urine and tissue. The technology is based on special antibodies and enables early detection of possible side effects during the drug development process. The company will use the €600K seed funds to advance development of its biomarker assay system. Signatope has already secured a number of renowned companies in the pharmaceutical and chemical industries as clients. Founded in August 2016 by Hannes Planatscher, Thomas Joos, Octavian Schatz and Oliver Pötz (CEO), the company is based in Reutlingen, Germany. The seed investment was made by High‑Tech Gründerfonds.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

May 2017